EUVIMEDEUVIMED entdecken
Crossref

Impact of Tafamidis on Echocardiographic Cardiac Function of Patients With Transthyretin Cardiac Amyloidosis

Yasushi Ichikawa, Eri Oota, Susumu Odajima, Masayuki Kintsu, Saki Todo, Kimikazu Takeuchi, Yuki Yamauchi, Hiroaki Shiraki, Kentaro Yamashita, Terunobu Fukuda, Eriko Hisamatsu, Ken-Ichi Hirata und 1 weitere

Circulation Journal · 2023

DOI: 10.1253/circj.cj-22-0683 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation Journal, 2023. Verfasst von Yasushi Ichikawa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The efficacy of a therapy for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) has not been proven, but tafamidis has been associated with favorable outcomes. However, echocardiographic details of the association of tafamidis with cardiac morphology remain undetermined. Moreover, whether the efficacy of tafamidis varies with the degree of cardiac involvement remains unknown. Using echocardiography, this study investigated the impact of tafamidis on the cardiac morphology of patients with ATTR-CM. METHODS AND RESULTS: Of 52 consecutive patients with biopsy-proven ATTR-CM at Kobe University Hospital, we included 41 for whom details of follow-up echocardiographic examinations after the administration of tafamidis were available. All patients underwent standard and speckle-tracking echocardiography before and a mean (±SD) of 16±8 months after the administration of tafamidis. No significant changes were observed in any representative echocardiographic parameters after the administration of tafamidis. Furthermore, there were no significant changes observed in subgroup analyses (e.g., left ventricular [LV] ejection fraction ≥50% vs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialCardiomyopathiesHumansAgedPrealbuminEchocardiographyBenzoxazoles

Stichwörter der Autor:innen

EchocardiographyTafamidisTransthyretin amyloid cardiomyopathy

Substanzen

PrealbumintafamidisBenzoxazoles

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine.

Zitieren

APA

Ichikawa, Y., Oota, E., Odajima, S., Kintsu, M., Todo, S., Takeuchi, K., Yamauchi, Y., Shiraki, H., Yamashita, K., Fukuda, T., Hisamatsu, E., Hirata, K. I., & Tanaka, H. (2023). Impact of Tafamidis on Echocardiographic Cardiac Function of Patients With Transthyretin Cardiac Amyloidosis. Circulation Journal. https://doi.org/10.1253/circj.cj-22-0683

Vancouver

Ichikawa Y, Oota E, Odajima S, Kintsu M, Todo S, Takeuchi K, et al. Impact of Tafamidis on Echocardiographic Cardiac Function of Patients With Transthyretin Cardiac Amyloidosis. Circulation Journal. 2023. doi:10.1253/circj.cj-22-0683

BibTeX
@article{Ichikawa2023,
  author = {Ichikawa, Yasushi and Oota, Eri and Odajima, Susumu and Kintsu, Masayuki and Todo, Saki and Takeuchi, Kimikazu and Yamauchi, Yuki and Shiraki, Hiroaki and Yamashita, Kentaro and Fukuda, Terunobu and Hisamatsu, Eriko and Hirata, Ken-Ichi and Tanaka, Hidekazu},
  title = {Impact of Tafamidis on Echocardiographic Cardiac Function of Patients With Transthyretin Cardiac Amyloidosis},
  journal = {Circulation Journal},
  year = {2023},
  doi = {10.1253/circj.cj-22-0683}
}
Kostenlos starten →